Company intelligence / Profile preview

SmartCells

Beverly, Massachusetts, United States

Ownership: Private
Employees: ~17
Development stage: Other

Overview

SmartCells was a biotech startup out of MIT developing SmartInsulin, a glucose-responsive insulin therapy. Its core platform enabled auto-regulated drug release based on molecular biomarkers. At the time of its acquisition by Merck in December 2010 for up to $500 million, SmartInsulin had demonstrated preclinical proof of concept in animal models but had not entered clinical trials. Merck acquired SmartCells to further clinical progress and commercialization potential of this technology.

Therapeutic areas: Endocrinology
Modalities: BiologicPolymer-drug conjugate therapy
Industry: Biotech

Beyond the preview

Go deeper on SmartCells.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SmartCells.

Explore the full profile